CXCR4 and cancer: They mainly concern the CXCR4 peptide inhibitor LY2510924 (NCT02737072), the anti-CXCR4 antibody LY2624587 (NCT01139788), the small molecule inhibitors Plerixafor (NCT20179970, NCT03277209), MSX-122 (NCT00591682, suspended), USL311 (NCT02765165); however, for a number of these trials, the cancer type is not always indicated, as it only specified that the targeted diseases are solid tumors.